About Specific Technologies
Specific Technologies is a company based in San Francisco (United States) founded in 2009 by Paul Rhodes and Ray Martino was acquired by BioMerieux in April 2022. Specific Technologies has raised $30 million across 2 funding rounds from investors including BioMerieux and Telegraph Hill Partners. Specific Technologies operates in a competitive market with competitors including Cepheid, Day Zero Diagnostics, SeLux Diagnostics, SpinDiag and MicrobeDx, among others.
- Headquarter San Francisco, United States
- Founders Paul Rhodes, Ray Martino
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website specificdx.com
- Social LinkedIn X Facebook
- Acquired by BioMerieux (Apr 2022)
- Total Equity Funding$30M (USD)
in 2 rounds
- Latest Funding Round$17.5M (USD), Series A
Feb 2020
- InvestorsBioMerieux
& 1 more
- Acquired byBioMerieux
(Apr 2022)
Funding Insights of Specific Technologies
Specific Technologies has successfully raised a total of $30M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $17.5 million completed in February 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $30M
- Total Rounds 2
- Last Round Series A — $17.5M
- First Round $12.5M
(Sep 2019)
- Investors Count 1
All 2 funding rounds of Specific Technologies with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2020 | $17.5M | Series A | – | – | – |
| Sep 2019 | $12.5M | Series B | – | Telegraph Hill Partners | – |
2 investors in total: 2 institutional.
Investors in Specific Technologies
Specific Technologies has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include BioMerieux and Telegraph Hill Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm focused on life science, medical device and healthcare companies | – | thpartners.net | San Francisco, United States | |
Developer of diagnostics devices for multiple health purposes | 1963 | biomerieux.com | - |
Investor details for Specific Technologies
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Specific Technologies
17 people are tracked at Specific Technologies (3 in leadership, 11 in board & advisors, 3 in team).
| Name | Role | Group |
|---|---|---|
Paul Rhodes | Co-Founder & CEO | Leadership |
Ray Martino | Founder | Leadership |
Richard Huang | Senior Director of Mechanical Engineering | Leadership |
Caroline Visser | Scientific Advisor, UK | Board & advisors |
Susan Sharp | Scientific Advisor, US | Board & advisors |
Hilmar Wisplinghoff | Scientific Advisor, UK | Board & advisors |
Kenneth Suslick | Scientific Advisor, US | Board & advisors |
Ellen Jo Baron | Scientific Advisor, US | Board & advisors |
David Alland | Scientific Advisor, US | Board & advisors |
Nathan Ledeboer | Scientific Advisor, US | Board & advisors |
Robin Patel | Scientific Advisor, US | Board & advisors |
Sharon Peacock | Scientific Advisor, UK | Board & advisors |
Martin Rottman | Scientific Advisor, UK | Board & advisors |
Romney Humphries | Scientific Advisor, US | Board & advisors |
Meiling Wu | V.p Manufacturing | Team |
Sandra Sanchez | Inventory And Logistics Manager | Team |
Jeffrey Seidler | Finance, Operations, And Development | Team |
Complete people profiles for Specific Technologies
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Specific Technologies
4 dated milestones of Specific Technologies across 13 years, from founding to its latest funding, stage changes and deals.
- Founded Specific Technologies is founded.
- Funding First funding round of $12.5M.
- Funding Latest funding round, Series A, of $17.5M.
- Exit Acquired by BioMerieux.
Competitors of Specific Technologies
Specific Technologies operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Cepheid, Day Zero Diagnostics, SeLux Diagnostics, SpinDiag and MicrobeDx, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| cepheid.com | 1996 | Sunnyvale, United States | $19.1M | 1,299 | Developer of molecular diagnostic testing solutions | |
| dayzerodiagnostics.com | 2016 | Boston, United States | $48.6M | 48 | Genome sequencing diagnostics for infectious diseases are developed. | |
| seluxdx.com | 2014 | Cambridge, United States | $161.01M | – | Developer of alternatives to traditional ELISA assays | |
| spindiag.de | 2016 | – | $27.69M | – | Point-of-care systems for screening drug-resistant pathogens are developed. | |
| microbedx.com | 2015 | Los Angeles, United States | $6.21M | – | Provider of the solutions for the detection of antibiotic susceptibility in urinary tract infections | |
| insilixa.com | 2012 | Sunnyvale, United States | $13M | 40 | Develops innovative point-of-care diagnostics using semiconductor-based CMOS biochip technology. | |
| astekdx.com | 2020 | Baltimore, United States | $3.23M | – | Blood test diagnostic devices are manufactured by Astek Diagnostics. |
Detailed competitors of Specific Technologies
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Specific Technologies
Complete news archive for Specific Technologies
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Specific Technologies
10 companies that operate in the same segment as Specific Technologies (Infectious Diseases), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 | |
Therapeutics for drug-resistant bacterial infections are developed. | 2013 | Cambridge, Massachusetts, United States | USD 114.7 M | USD 59.62 M | 32 | |
Clinical diagnostics and drug discovery for immune diseases are provided. | 2009 | Seattle, Washington, United States | USD 419.15 M | USD 276.98 M | 619 | |
Vaccines for infectious diseases are developed using cell-free protein synthesis. | 2013 | Foster City, California, United States | USD 347 M | – | 414 | |
Portable PCR diagnostics for infectious diseases are developed. | 2010 | San Jose, California, United States | USD 386.33 M | – | – | |
Developing glucan synthase inhibitors for the treatment of fungal infections. | 1999 | Jersey City, New Jersey, United States | USD 62.65 M | USD 20.6 M | 28 | |
Sherlock Biosciences is focused on molecular diagnostics development. | 2019 | Watertown, United States | USD 111 M | – | 33 | |
Provider of diagnostic solutions for systemic infections | 2016 | San Francisco, California, United States | USD 191.47 M | – | 54 | |
Developer of novel protein-based therapeutics using machine learning and biological engineering | 2018 | Somerville, Massachusetts, United States | USD 693 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Specific Technologies
Specific Technologies was founded in 2009 and raised its 1st funding round 10 years after it was founded.
Specific Technologies is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Paul Rhodes is the current CEO of Specific Technologies. They have also founded this company.
Specific Technologies is a funded company, having raised a total of $30M across 2 funding rounds to date. The company's 1st funding round was a Series B of $12.5M, raised on Sep 2019.
Specific Technologies was founded in 2009 and is based in San Francisco, United States. Operations focus on the diagnostics sector, where blood infection detection and antibiotic susceptibility testing are conducted. Two products, Reveal AST and Reveal ID, are offered, both supporting susceptibility assessments. Leadership includes co-founder and CEO Paul Rhodes, alongside founder Ray Martino. Services target healthcare applications in infection management.
Specific Technologies's top competitors include Cepheid, Day Zero Diagnostics and SeLux Diagnostics.
Specific Technologies has 2 investors. Key investors include BioMerieux, and Telegraph Hill Partners.
Yes. Specific Technologies was acquired by BioMerieux in April 2022.